Psoriasis vulgaris, or chronic plaque psoriasis, is the most common form of psoriasis disease, making up 85-90% of cases.1 With psoriasis affecting 1.3-2.2% of people in the UK2, this means that at least 1.1% of the population have plaque psoriasis in the UK. In Ireland, we see that 1.6% of the population have psoriasis3, meaning that the prevalence of plaque psoriasis is around 1.4%.
Learn more about the condition and LEO Pharma’s commitment to improving the lives of patients with plaque psoriasis.
Atopic dermatitis is one of the most common skin conditions in the world. LEO Pharma is committed to improving the lives of people living with this painful and itchy dermatological condition.
- Palfreeman, A. C., McNamee, K. E., & McCann, F. E. (2013). New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug design, development and therapy, 7, 201–210. doi:10.2147/DDDT.S32713
- NICE. CG153. Psoriasis: assessment and management (October 2012). Available at: https://www.nice.org.uk/guidance/Cg153. Accessed September 2018
- Irish Skin Foundation. Report: The Burden of Psoriasis. Available at: https://irishskin.ie/wp-content/uploads/2016/08/Burden_of_Psoriasis_Report_final.pdf. Accessed September 2018.